Scarica l'app Stockscreener
194.95
0.38%
0.73
Dopo l'orario di chiusura:
194.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu - marketscreener.com
AstraZeneca (AZN) Achieves Priority Review for Enhertu in Breast Cancer Treatment - GuruFocus
AstraZeneca, Daiichi Sankyo Wins Priority Review for Enhertu for Breast Cancer - marketscreener.com
AstraZeneca (AZN) and Other Drugmakers Watch as Key FDA Official Resigns - GuruFocus
AstraZeneca’s AZD5004 Formulation Trial: Early Data Point for Long-Term Pipeline Value - TipRanks
AstraZeneca executives receive vested shares under deferred bonus plan - Investing.com India
AstraZeneca CEO Pascal Soriot receives vested shares under performance plan - Investing.com UK
AstraZeneca awards share grants to CEO and CFO under company incentive plans - Investing.com Nigeria
AstraZeneca (AZN) CEO awarded 101,495 shares on AZPSP vesting - Stock Titan
AstraZeneca (NYSE: AZN) awards deferred bonus shares to leaders - Stock Titan
Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial - Proactive Investors
Longfellow Investment Management Co. LLC Makes New Investment in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Stock Holdings Raised by Orion Porfolio Solutions LLC - MarketBeat
AstraZeneca Executives Receive Vested Deferred Share Awards - TipRanks
AstraZeneca Grants Long-Term Share Awards to CEO and CFO - TipRanks
The Zacks Analyst Blog Highlights Exxon Mobil, Palantir, AstraZeneca, Gencor Industries and Hour Loop - Yahoo Finance Singapore
243,177 Shares in AstraZeneca PLC $AZN Purchased by Foresight Global Investors Inc. - MarketBeat
Top Analyst Reports for Exxon Mobil, Palantir & AstraZeneca - Yahoo Finance
GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 - GlobeNewswire Inc.
HAP Trading LLC Sells 7,267 Shares of AstraZeneca PLC $AZN - MarketBeat
Mengis Capital Management Inc. Boosts Stock Position in AstraZeneca PLC $AZN - MarketBeat
Dimensional Fund Advisors LP Raises Stake in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Position Lessened by Teachers Retirement System of The State of Kentucky - MarketBeat
AstraZeneca (AZN) Strengthens Clinical Portfolio and Expands Inv - GuruFocus
GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.
CI Investments Inc. Has $18.33 Million Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Tezepelumab Study Targets Real-World Gains in Chronic Sinus Disease - TipRanks
AstraZeneca (AZN) adds three fixed-rate US dollar note issues out to 2036 - Stock Titan
AstraZeneca PLC (AZN) Investor Outlook: Evaluating the Healthcare Giant Amidst a -21.01% Potential Downside - DirectorsTalk Interviews
Morqan Stanley Raises Astrazeneca Price Target to $219 From $109, Overweight Rating Kept - marketscreener.com
AstraZeneca reports total voting rights of over 1.55 billion shares - Investing.com
AstraZeneca (LSE/STO/NYSE: AZN) details 1.55B voting rights - Stock Titan
Fisher Asset Management LLC Acquires 466,745 Shares of AstraZeneca PLC $AZN - MarketBeat
ASTRAZENECA : JP Morgan maintains a Buy rating - marketscreener.com
Rafferty Asset Management LLC Sells 7,892 Shares of AstraZeneca PLC $AZN - MarketBeat
Becker Capital Management Inc. Decreases Position in AstraZeneca PLC $AZN - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review - marketscreener.com
American Century Companies Inc. Has $167.79 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC (AZN.L) Stock Report: Analyzing a Healthcare Powerhouse with a $241 Billion Market Cap - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
AstraZeneca PLC $AZN Shares Bought by US Bancorp DE - MarketBeat
Harvest Portfolios Group Inc. Sells 20,219 Shares of AstraZeneca PLC $AZN - MarketBeat
AlphaCore Capital LLC Increases Stock Position in AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLC $AZN Shares Acquired by TD Asset Management Inc - MarketBeat
Erste Asset Management GmbH Sells 29,313 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange - FinancialContent
Thornburg Investment Management Inc. Sells 24,703 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca has 'sector leading replacement power' to cope with 2030 patent cliff - Yahoo Finance UK
AstraZeneca (AZN) prices $2bn in new fixed-rate global bond tranches - Stock Titan
AstraZeneca prices $2 bln bond offering - marketscreener.com
Primecap Management Co. CA Sells 1,342,120 Shares of AstraZeneca PLC $AZN - MarketBeat
RWA Wealth Partners LLC Purchases 6,444 Shares of AstraZeneca PLC $AZN - MarketBeat
AstraZeneca PLCAstraZeneca prices a $2bn bond offering - Research Tree
AstraZeneca Prices Three-tranche Global Bond Issue Worth $2 Billion - marketscreener.com
REGAstraZeneca PLCAstraZeneca prices a $2bn bond offering - TradingView
AstraZeneca’s Soriot Rewarded With $23m Pay But Still Lags Behind US Peers - Citeline News & Insights
AstraZeneca Advances Subcutaneous Durvalumab Study, Targeting More Convenient Cancer Care - TipRanks
Astrazeneca files 2025 annual report on Form 20-F with SEC - Investing.com
Astrazeneca files 2025 annual report on Form 20-F with SEC By Investing.com - Investing.com South Africa
AstraZeneca (AZN) files 2025 Form 20-F annual report with US SEC - Stock Titan
Compound Planning Inc. Has $2.53 Million Stock Holdings in AstraZeneca PLC $AZN - MarketBeat
Medicines: Oncology Portfolio and Pipeline - AstraZeneca
Assessing AstraZeneca (LSE:AZN) Valuation After Strong Recent Share Price Momentum - simplywall.st
[6-K] ASTRAZENECA PLC Current Report (Foreign Issuer) | AZN SEC FilingForm 6-K - Stock Titan
AstraZeneca (AZN) files Iran‑related disclosure in 20‑F annual report - Stock Titan
AstraZeneca Drug Price Challenge Falls Short In Hawaii - Law360
1.67%
1.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):